If you’ve ever heard that menopausal hormone therapy can increase the risk of breast cancer, this new health report may surprise you. 

In this bonus episode, women’s health and menopause management expert Dr. Mindy Goldman sheds light on the complex world of Menopause Hormone Therapy. We explore pivotal insights from the Ester Trial, revealing potentially safer transdermal estrogen. We talk about a fascinating Today article that uncovers the impact of statistical manipulation on reported studies, especially concerning the relationship between breast cancer and hormone therapy.

Dr. Mindy Goldman shares her expert opinion on how estrogen alone might be safer than we thought, and why synthetic progesterone requires a closer look. We also discuss the controversial use of testosterone in women, the challenges with federal laws, and FDA-approved options for improving libido.

Dr. Goldman is a Clinical Professor in the Department of OB/GYN at UCSF and the Director of the Gynecology Center for Cancer Survivors and At-Risk Women. In addition to her role as Midi’s Chief Clinical Officer, she’s a nationally recognized expert in the management of women’s health issues, including menopause, for women with cancer or at high risk. She helped author guidelines for the American College of Obstetrics and Gynecology (ACOG) and has won several notable awards.

Discussed in this episode:

• Dr. Mindy’s work with breast cancer survivors as an OBGYN
• Common myths of menopause hormone therapy
• A discussion on the ESTHER Study and recent menopause data release in Today
• Risks and safety of estrogen, progesterone, and testosterone therapy
• FDA-approved drugs for women’s sexual function 
• Gender disparities in medical research 
• Hormone therapies and other treatment options for high-risk populations such as cancer survivors 
• Menopause symptoms in breast cancer treatment 
• Hormone therapies, medications, and lifestyle strategies as post-cancer treatment options 
• Dr. Mindy Goldman’s professional experience as a menopause advocate combining breast oncology with gynecology

“It's important to realize that there aren't national guidelines that talk about the use of hormones in people at high risk for cancer, which includes people with a family history, people who have had prior biopsies with atypical change, people with genetic mutations, and people with cancer. The standard of care has always been not to use hormones in those situations because the thought was that hormones could increase the risk of breast cancer or increase the behavior of breast cancer.” - Dr Mindy Goldman

Related to this episode:

• Resources and episodes on Perimenopause & Menopause and sign up for the Perimenopause and Menopause newsletter

• Menopause health report (Dec 2023): https://pubmed.ncbi.nlm.nih.gov/37847875 
• ESTHER Study: Learn more.
• Dr. Goldman’s story: www.joinmidi.com/post/mindy-goldman 
• Dr. Mindy Goldman on Linkedin
• Midi Health: www.joinmidi.com 
• Menopause book recommendations: www.bookshop.org/lists/top-picks-for-menopause

🎧 Loved the episode? Here's how you can take action:

1. Help others discover Fempower Health:

Leave a quick review on Apple or Spotify. It’s the easiest way to support our mission and amplify women’s health voices.

2. Stay connected:

Follow us on LinkedIn, Instagram and TikTok, YouTube for real-time updates, expert insights, and relatable conversations.

Or join our newsletter to get curated women's health content—on your terms, in your inbox.

**Top 50 Health Podcast of 2024**

**The information shared by Fempower Health is not medical advice but for informational purposes to enable you to have more effective conversations with your doctor.  Always talk to your doctor before making health-related decisions. Additionally, the views expressed by the Fempower Health podcast guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.**

**May contain affiliate links and I will be compensated if you make a purchase after clicking on my links**